PEMBROLIZUMAB AND BEVACIZUMAB IN PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS

被引：1
|
作者：
Michels, Judith [1 ]
Frenel, Jean-Sebastien [2 ]
Genestie, Catherine [3 ]
Ghiringhelli, Francois [4 ]
Brard, Caroline [3 ]
You, Benoit [5 ]
Floquet, Anne [6 ]
Eberst, Lauriane [7 ]
Bahleda, Rastilav [1 ]
Balleyguier, Corinne [1 ]
Paci, Angelo [1 ]
Ciccolini, Joseph [8 ]
Colomba, Emeline [1 ]
Pommeret, Fanny [1 ]
Massard, Christophe
Pautier, Patricia [1 ]
Marabelle, Aurelien [1 ]
Leary, Alexandra [1 ]
机构：
[1] Gustave Roussy Inst, Paris, France
[2] Inst Cancerol IOuest, St Herblain, France
[3] Gustave Roussy, Villejuif, France
[4] Ctr Georges Francois Leclerc, Dijon, France
[5] Inst Cancerol Hosp Ci, Lyon, France
[6] Inst Bergonie, Bordeaux, France
[7] Inst Cancerol Strasbourg, Strasbourg, France
[8] La Timone Univ Hosp, Marseille, France
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.355
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
355
引用
收藏
页码：A382 / A382
页数：1
相关论文
共 50 条
  • [21] Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients
    Hansen, Mads Kingo Guldberg
    Smerdel, Maja Patricia
    Waldstrom, Marianne
    Andersen, Rikke Fredslund
    Adimi, Parvin
    Jakobsen, Anders
    Steffensen, Karina Dahl
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (06) : 751 - 759
  • [22] Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
    Liu, Ying
    Ren, Zhonghai
    Xu, Shuning
    Bai, Hua
    Ma, Ning
    Wang, Feng
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 645 - 651
  • [23] Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
    Ying Liu
    Zhonghai Ren
    Shuning Xu
    Hua Bai
    Ning Ma
    Feng Wang
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 645 - 651
  • [24] Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine
    Komiyama, Shinichi
    Kugimiya, Tsuyoki
    Takeya, Chiaki
    Takahashi, Rena
    Kubushiro, Kaneyuki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2018, 44 (07) : 1330 - 1334
  • [25] Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab
    Sostelly, Alexandre
    Mercier, Francois
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2019, 13
  • [26] A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
    Cui, Qingli
    Hu, Yanhui
    Ma, Dongyang
    Liu, Huaimin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 339 - 347
  • [27] PHASE 2 TRIAL OF WEEKLY PACLITAXEL WITH PEMBROLIZUMAB IN PLATINUM RESISTANT RECURRENT OVARIAN CANCER
    Wenham, R. M.
    McGuire, W.
    Fridley, B.
    Boulware, D.
    Apte, S.
    Chon, H.
    Shahzad, M.
    Secord, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 20 - 20
  • [28] Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
    Walsh, Christine S.
    Kamrava, Mitchell
    Rogatko, Andre
    Kim, Sungjin
    Li, Andrew
    Cass, Ilana
    Karlan, Beth
    Rimel, Bobbie J.
    PLOS ONE, 2021, 16 (06):
  • [29] Monotherapy with gemcitabine in elderly patients with relapsed or persistent epithelial ovarian cancer (EOC) platinum resistant
    Capobianco, A. M. L.
    Ardito, R.
    Bochicchio, A. M.
    Coccaro, M.
    Di, Leo P.
    Romano, C.
    Tartarone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 187 - 187
  • [30] Monotherapy with gemcitabine in elderly patients with relapsed or persistent epithelial ovarian cancer (eoc) platinum resistant
    Aml, Capobianco
    Ardito, R.
    Am, Bochicchio
    Coccaro, M.
    Di, Leo P.
    Romano, C.
    Tartarone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 187 - 187
12345